Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis Oncology: You Should Embrace Volatility To Enjoy Profitability

Clovis Oncology Inc. (CLVS) CEO Patrick Mahaffy has made it clear he wants to sell the Boulder, Colorado-based biotech, which focuses on developing cancer drugs.

Clovis Oncology Needs a Savior

Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday. Late Monday, the company announced a common stock offering of $85 million.

Why Clovis Oncology's Stock Is Trading Lower Today

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer

Rubraca is the first PARP inhibitor approved for prostate cancer.

Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) shares traded higher on Friday afternoon after the company announced the FDA approved its Rubraca tablets for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.

Why Clovis Oncology's Stock Spiked Higher Today

Apple

SPDR S&P 500 ETF Trust

Wells Fargo

Spirit Airlines

Apple, the S&P 500 ETF, Clovis Oncology, Spirit Airlines and Wells Fargo were our top stock trades to watch going into Thursday.

5 Top Stock Trades for Thursday: AAPL, SPY, WFC, CLVS, SAVE

Clovis Oncology's stock reversed course last month.

Why Clovis Oncology Stock Marched Higher in April

AstraZeneca

Gilead Sciences

Bristol-Myers

Merck

Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.

From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now

Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues.

Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2020 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates

Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.

Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology

Clovis Oncology: An Undervalued Diamond In The Rough

Immunomedics

Puma Biotechnology

Investors piled into cancer stocks. Here's why.

Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today

Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session.

Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know

Clovis: Coronavirus Bear Market Overreaction

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?

Clovis Oncology (CLVS) closed the most recent trading day at $4.50, moving +0.45% from the previous trading session.

Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know

Clovis: Market Volatility Provides Opportunity To Reload

Clovis Oncology (CLVS) closed the most recent trading day at $6.17, moving -1.59% from the previous trading session.

Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know

The biotech is getting special attention from the moody market today. Here's why.

Why Clovis Oncology Stock Is Tanking Today

Amcor Plc

Gerdau

Kinross Gold

SunPower

How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears

The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.

Here's Why Clovis Oncology Has Upside Potential in 2020

Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues.

News for Clovis Oncology Stock (CLVS)